Entity > Corporation > US > New York City New York > Tarsus Pharmaceuticals
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company. Tarsus Pharmaceuticals, Inc. is focused on the development and commercialization of therapeutic candidates to address large market opportunities.
Tarsus Pharmaceuticals, Inc. Applies Proven Science And New Technology To Revolutionize Treatment For Patients: Tarsus Pharmaceuticals, Inc. is advancing its pipeline to address multiple diseases across therapeutic categories, including ophthalmology, dermatology, and other diseases with high unmet needs. Tarsus Pharmaceuticals, Inc.'s lead product candidate, TP -03, is a Phase 2b/3 novel therapeutic being developed for the treatment of Demodex blepharitis. With our unique research and development approach, Tarsus Pharmaceuticals, Inc. is investigating solutions for MGD, rosacea, Lyme disease prevention, and community malaria control.
Tarsus Pharmaceuticals, Inc.’s Founding and Headquarters: Tarsus Pharmaceuticals, Inc. was founded in 2017 by Bobak Azamian. Tarsus Pharmaceuticals, Inc. is currently headquartered in Irvine, California, USA.
Industry: Business & Industrial > Pharmaceuticals & Biotech
More information about Tarsus Pharmaceuticals
| Company Attribute | Value |
| Name | Tarsus Pharmaceuticals |
| Url | tarsusrx |
Tarsus Pharmaceuticals
New York City, US
11 Sep 2023
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals (Pharmaceutical company)
Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapeutics. The Company's lead product candidate, TP-03, is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites (Demodex blepharitis).
-
Stock price : TARS (NASDAQ) $16.05 +0.55 (+3.55%)Sep 8, 4:00 PM EDT - Disclaimer
-
Headquarters : Irvine, CA
-
Founded : 2016
-
Ceo : Bobak Azamian cbinsights.com